Form 8-K - Current report:
SEC Accession No. 0001193125-25-014413
Filing Date
2025-01-28
Accepted
2025-01-28 16:31:54
Documents
13
Period of Report
2025-01-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d883134d8k.htm   iXBRL 8-K 29096
  Complete submission text file 0001193125-25-014413.txt   158017

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apto-20250127.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250127_lab.xml EX-101.LAB 19468
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250127_pre.xml EX-101.PRE 12148
15 EXTRACTED XBRL INSTANCE DOCUMENT d883134d8k_htm.xml XML 3902
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25564693
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)